logo-loader
HealthPharma & Biotech
Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals makes new breakthrough for iPPS, shares rise

New clinical trial data shows that its trial drug Zilosul (iPPS) also reduces knee cartilage degradation.

Paradigm Biopharmaceuticals Ltd - Paradigm Biopharmaceuticals makes new breakthrough for iPPS, shares rise
Exploratory endpoints reveal important breakthrough

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has made a valuable discovery during its phase IIb osteoarthritis (OA) clinical trial.

Two biomarkers known as COMP and ADAMTS-5, which are found in patients with progressive OA, have been reducing upon treatment with Zilosul.

Zilosul is the name for Paradigm’s flagship trial drug, injectable pentosan polysulfate sulfate (iPPS)

Paradigm considers this a major new discovery which adds to the clinical evidence that Zilosul could materially impact the progression of a disease that previously was thought to have no effective disease modifying treatment options.

More data expected over coming months

Paradigm’s CEO Paul Rennie said: “We are very pleased to demonstrate that iPPS was able to reduce levels of the biochemical markers COMP and ADAMTS-5 which predict disease progression in OA.

“Of important relevance for Paradigm’s clinical development is that the biomarker results further validate the objective measures of the therapeutic effects of iPPS in association with the objective MRI reduction of subchondral BML and the clinically meaningful reduction of pain.

“Paradigm is expecting the release of more biomarker data in the coming months as the results are provided to the company by the reference laboratory."

Cartilage breakdown associated with OA & levels of COMP & ADAMTS-5

Summary of findings

Put simply, COMP & ADAMTS-5 are reliable indicators of progressively worsening OA, meaning, those patients with elevated levels of these biomarkers in their blood have experienced an increased level of cartilage degeneration.

As the cartilage around the joint breaks down, these biomarkers found in the joint cartilage are released into the blood. Cartilage degeneration is the hallmark outcome of patients with progressive OA.

The discovery by Paradigm, that patients treated with Zilosul saw a meaningful reduction in these biomarkers when compared to the placebo arm. This discovery appears to indicate that treatment with Zilosul protects, slows or stops the cartilage around the joint from degrading – slowing the progression of the disease.

Paradigm got more than they bargained for with clinical trial data

Rennie added “The most pleasing outcome of the phase IIb clinical trial was the positive correlation between the clinical outcomes and the objectively measured structural outcomes.

“The clinical outcomes saw the reduction in pain and improvement in joint function AND additionally the objective disease-modifying outcomes of reduced BML and reduction of cartilage degrading biomarkers.”

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: $2.28

Market: ASX
Market Cap: $438.63 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Clinigen Group reports on 'transformational' year with strong profit growth

Clinigen Group PLC's (LON:CLIN) head of investor relations Matt Parrish caught up with Proactive London's Andrew Scott following the release of the firm's results for the year to June 2019. The firm's gross profit was up 30% at £182.3mln, while revenues were ahead 20% at £456.9mln. Underlying...

15 hours, 2 minutes ago

2 min read

;